FDA Warning Letter criticizes Supplier Qualification

Recommendation
11-13 November 2025
Vienna, Austria
An advanced Auditor Course with many interactive Sessions and practical Examples
CMO Supplier Qualification and the respective contracts in outsourcing activities are always hot topics in inspections. The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter sent to a pharmaceutical company in the US criticizing their supplier qualification and oversight. The inspection was scheduled because of problems at the company's CMO.
For example, the company "failed to have adequate supplier qualification procedures to ensure that the drug products received" from CMOs "were manufactured in compliance with CGMP." They also "failed to have adequate procedures" to ensure tht all drug products produced for the firm met "appropriate quality attributes".
The company now has to evaluate the supplier and CMO qualification program, "including a plan to conduct periodic audits". In the Warning Letter, the FDA clearly points out that the company is responsible for the quality of the drugs "regardless of agreements in place" with CMOs.
Related GMP News
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published
03.09.2025FDA Report on the State of Pharmaceutical Quality
27.08.2025Bizarre Findings in FDA Warning Letters